Prognostic Significance of FOXC1 in Various Cancers: A Systematic Review and Meta-Analysis.
Journal
Molecular diagnosis & therapy
ISSN: 1179-2000
Titre abrégé: Mol Diagn Ther
Pays: New Zealand
ID NLM: 101264260
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
pubmed:
3
8
2019
medline:
19
5
2020
entrez:
3
8
2019
Statut:
ppublish
Résumé
Forkhead box C1 (FOXC1), a member of the Forkhead box (Fox) transcription factor family, plays an essential role in lymphatic vessel formation, angiogenesis and metastasis. Observational studies examining the relationship between the protein biomarker FOXC1 and breast cancer prognosis have reported conflicting findings. This systematic review and meta-analysis evaluates the prognostic value of the FOXC1 expression in association with patient survival in breast cancer and other types of cancers in order to identify the overall prognostic effectiveness of FOXC1. This study followed the guidelines established in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). We conducted a broad search on the online bibliographic databases EMBASE, PubMed, Science Direct and Scopus, limiting search to publications from 2010 to 2018. The prognostic value was demonstrated by a random effects model meta-analysis using the hazard ratio (HR) with 95% confidence interval (CI) for overall survival (OS) in various cancer patients. The heterogeneity was measured by the I A total of 16 studies met the predefined selection criteria established for our systematic review and meta-analysis, with multiple studies using diverse methodologies and reported on differing clinical outcomes, falling under a common banner of FOXC1 expression and survival in cancer. Overall, we observed a statistically non-significant association between FOXC1 protein expression and patients survival (HR: 1.186 and 95% CI 1.122-1.255, p = 0.000, I In summary, FOXC1 protein expression indicated poor survival outcome in various carcinomas, especially in patients with breast cancer, suggesting it as a possible biomarker for the prognosis in multiple carcinomas. Further clinical evaluation and large-scale cohort studies are required to accurately identify its possible clinical utility.
Sections du résumé
BACKGROUND
Forkhead box C1 (FOXC1), a member of the Forkhead box (Fox) transcription factor family, plays an essential role in lymphatic vessel formation, angiogenesis and metastasis. Observational studies examining the relationship between the protein biomarker FOXC1 and breast cancer prognosis have reported conflicting findings. This systematic review and meta-analysis evaluates the prognostic value of the FOXC1 expression in association with patient survival in breast cancer and other types of cancers in order to identify the overall prognostic effectiveness of FOXC1.
METHODS
This study followed the guidelines established in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). We conducted a broad search on the online bibliographic databases EMBASE, PubMed, Science Direct and Scopus, limiting search to publications from 2010 to 2018. The prognostic value was demonstrated by a random effects model meta-analysis using the hazard ratio (HR) with 95% confidence interval (CI) for overall survival (OS) in various cancer patients. The heterogeneity was measured by the I
RESULTS
A total of 16 studies met the predefined selection criteria established for our systematic review and meta-analysis, with multiple studies using diverse methodologies and reported on differing clinical outcomes, falling under a common banner of FOXC1 expression and survival in cancer. Overall, we observed a statistically non-significant association between FOXC1 protein expression and patients survival (HR: 1.186 and 95% CI 1.122-1.255, p = 0.000, I
CONCLUSION
In summary, FOXC1 protein expression indicated poor survival outcome in various carcinomas, especially in patients with breast cancer, suggesting it as a possible biomarker for the prognosis in multiple carcinomas. Further clinical evaluation and large-scale cohort studies are required to accurately identify its possible clinical utility.
Identifiants
pubmed: 31372939
doi: 10.1007/s40291-019-00416-y
pii: 10.1007/s40291-019-00416-y
doi:
Substances chimiques
Biomarkers, Tumor
0
FOXC1 protein, human
0
Forkhead Transcription Factors
0
Types de publication
Journal Article
Meta-Analysis
Review
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
695-706Commentaires et corrections
Type : CommentIn
Type : CommentIn
Références
Ther Adv Med Oncol. 2017 Dec;9(12):797-816
pubmed: 29449899
J Exp Clin Cancer Res. 2018 Sep 6;37(1):220
pubmed: 30189871
Mol Diagn Ther. 2019 Feb;23(1):65-82
pubmed: 30726546
Am J Hum Genet. 2001 Feb;68(2):364-72
pubmed: 11170889
Cancer Res. 2010 May 15;70(10):3870-6
pubmed: 20406990
CA Cancer J Clin. 2017 Nov;67(6):439-448
pubmed: 28972651
Cell Rep. 2015 Nov 3;13(5):1046-58
pubmed: 26565916
Int J Clin Exp Pathol. 2014 May 15;7(6):2838-49
pubmed: 25031703
Ann Surg Oncol. 2011 Dec;18(13):3839-47
pubmed: 21424368
ILAR J. 2014;55(3):418-26
pubmed: 25541544
J Biol Chem. 2002 Mar 22;277(12):10292-7
pubmed: 11782474
Biomed Pharmacother. 2017 Oct;94:1038-1047
pubmed: 28810526
Proc Natl Acad Sci U S A. 2010 Aug 31;107(35):15449-54
pubmed: 20713713
Oncotarget. 2018 Nov 27;9(93):36625-36630
pubmed: 30564302
PLoS One. 2019 Feb 8;14(2):e0209760
pubmed: 30735523
Cancer Sci. 2014 Oct;105(10):1288-98
pubmed: 25130698
Histopathology. 2014 Jun;64(7):963-70
pubmed: 24329718
Dis Markers. 2018 Oct 22;2018:6904569
pubmed: 30425753
Ann Intern Med. 2009 Aug 18;151(4):264-9, W64
pubmed: 19622511
J Natl Cancer Inst. 2015 Jun 03;107(8):
pubmed: 26041837
Syst Rev. 2018 Oct 2;7(1):150
pubmed: 30285880
Am J Hum Genet. 1998 Nov;63(5):1316-28
pubmed: 9792859
Cancer Manag Res. 2018 Oct 16;10:4669-4670
pubmed: 30410400
Cancer Chemother Pharmacol. 2017 Jun;79(6):1205-1213
pubmed: 28493031
Nat Rev Cancer. 2007 Nov;7(11):847-59
pubmed: 17943136
J Biol Chem. 2012 Jul 13;287(29):24631-40
pubmed: 22645147
Sci Rep. 2016 Jul 26;6:30437
pubmed: 27457567
Oral Oncol. 2018 Nov;86:312-313
pubmed: 30262125
Tumour Biol. 2013 Apr;34(2):941-6
pubmed: 23264086
Dev Biol. 1999 Jul 15;211(2):306-22
pubmed: 10395790
Sci Rep. 2016 Aug 22;6:31804
pubmed: 27545642
Jpn J Clin Oncol. 2017 Aug 1;47(8):690-698
pubmed: 28591777
Medicine (Baltimore). 2018 Dec;97(52):e13680
pubmed: 30593138
Hepatology. 2013 Feb;57(2):610-24
pubmed: 22911555
Mol Diagn Ther. 2018 Dec;22(6):653-669
pubmed: 30259393
Stat Med. 1998 Dec 30;17(24):2815-34
pubmed: 9921604
Am J Transl Res. 2017 Mar 15;9(3):1297-1306
pubmed: 28386355
Oncotarget. 2017 Nov 28;9(8):8165-8178
pubmed: 29487724
Int J Mol Sci. 2018 Oct 22;19(10):
pubmed: 30360388
Oncogene. 2017 Jul 13;36(28):3957-3963
pubmed: 28288141
Tumour Biol. 2013 Apr;34(2):853-8
pubmed: 23242609
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120